- Full Year 2023 HUTCHMED (China) Ltd Earnings Call TranscriptFeb 28, 2024£2.7Earnings
- HUTCHMED (China) Ltd at Deutsche Bank ADR Investor Conference (Virtual) TranscriptNov 09, 2023
- Half Year 2023 HUTCHMED (China) Ltd Earnings Call TranscriptJul 31, 2023£2.19Earnings
- HUTCHMED (China) Ltd at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- HUTCHMED (China) Ltd at Jefferies Healthcare Conference TranscriptJun 08, 2023
- HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Full Year 2022 HUTCHMED (China) Ltd Earnings Call TranscriptFeb 28, 2023£1.66Earnings
- HUTCHMED (China) Ltd Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China Call TranscriptJan 23, 2023
- HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank dbVIC ADR Virtual Investor Conference TranscriptNov 17, 2022
- HUTCHMED (China) Ltd at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- HUTCHMED (China) Ltd FRESCO-2 Data at ESMO Call TranscriptSep 12, 2022
- Half Year 2022 HUTCHMED (China) Ltd Earnings Call TranscriptAug 01, 2022£2.04Earnings
- HUTCHMED (China) Ltd Company Update: Surufatinib FDA NDA Status Corporate Call TranscriptMay 02, 2022
- Full Year 2021 HUTCHMED (China) Ltd Earnings Call TranscriptMar 03, 2022£4.08Earnings
- HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 17, 2021
- HUTCHMED (China) Ltd and Epizyme Inc Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® in Greater China Call TranscriptAug 09, 2021
- Half Year 2021 HUTCHMED (China) Ltd Earnings Call TranscriptJul 28, 2021£5.6Earnings
- HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- HUTCHMED (China) Ltd Corporate Call TranscriptMay 27, 2021
- HUTCHMED (China) Ltd virtual investor update Call TranscriptMay 26, 2021
- HUTCHMED (China) Ltd at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Full Year 2020 Hutchison China MediTech Ltd Earnings Call TranscriptMar 04, 2021£4.35Earnings
- Hutchison China MediTech Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Half Year 2020 Hutchison China MediTech Ltd Earnings Call TranscriptJul 30, 2020£4.07Earnings
- Hutchison China MediTech Ltd Investor Update at ASCO TranscriptJun 01, 2020
- Hutchison China MediTech Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Hutchison China MediTech Ltd at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 19, 2020
- Full Year 2019 Hutchison China MediTech Ltd Earnings Call TranscriptMar 03, 2020£3.9 (+8.33%)Earnings
- Hutchison China MediTech Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 13, 2019
- Hutchison China MediTech Limited - Special Call TranscriptSep 30, 2019
- Hutchison China MediTech Ltd at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Half Year 2019 Hutchison China MediTech Ltd Earnings Presentation TranscriptJul 30, 2019
- Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMay 15, 2019
- Full Year 2018 Hutchison China MediTech Ltd Earnings Call TranscriptMar 11, 2019Earnings
- Full Year 2018 Hutchison China MediTech Ltd Earnings Call TranscriptMar 11, 2019Earnings
HUTCHMED (China) Ltd at Jefferies Healthcare Conference Transcript
Good afternoon, everyone. Thank you for attending Jefferies' New York Healthcare Conference. We are very pleased to have Mr. Mark Lee, SVP of Corporate Finance and Development, and Ms. Karen Atkin, COO of HUTCHMED, for joining us today to share their insights on HUTCHMED.
Questions & Answers
First to start, maybe you can give us a brief overview and the strategy of HUTCHMED, before we get into details in your commercial and clinical pipeline.
()-
Thanks for the opportunity to be here, Kelly.
And yes, so, HUTCHMED, is an innovative biopharma company that's focused on innovative research in oncology and immunology. We've been going as a company for over 20 years now. We're triple listed on Nasdaq, Hong Kong and UK, a market capitalization of about at USD2.1 billion.
And we've been successful with our own research and development. We've got
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)